Decreased expression of SLC16A12 mRNA predicts poor prognosis of patients with clear cell renal cell carcinoma

Abstract

Solute carrier family 16, member 12 (SLC16A12) is a highly -expressed protein in the kidney and has been reported to participate in the transport of creatine. However, the clinical values of SLC16A12 in clear cell renal cell carcinoma (ccRCC) have not been explored. SLC16A12 RNA-seq data and clinical information were downloaded from the Cancer Genome Atlas (TCGA) database. We compared its expression in ccRCC and paracancerous tissues, then the result was further validated with our cohort. The impact on the clinical significance of SLC16A12 in ccRCC was also assessed. Compared with paracancerous tissue, SLC16A12 was significantly downregulated in the tumor tissues both in mRNA and protein level. In TCGA cohort, SLC16A12 mRNA expression was associated with several clinicopathological parameters, including T stages ( P < .001), M stages ( P = .009), TNM stages ( P < .001), and differentiated grades ( P = .001). Kaplan–Meier analysis showed that the overall survival of patients with low expression of SLC16A12 mRNA was significantly worse than that of patients with high expression ( P < .001). Furthermore, both univariate ( HR = 0.371, 95%CI : 0.269–0.513, P < .001) and multivariate ( HR = 0.485, 95%CI : 0.297–0.793, P = .004) Cox regression analyses suggested that low expression of SLC16A12 mRNA was an independent prognostic factor for patients with ccRCC. Overall, we uncovered that decreased expression of SLC16A12 is a poor prognostic factor for patients with ccRCC. SLC16A12 might be a potential biomarker and therapeutic target in ccRCC.

Construction and validation of a seven-gene signature for predicting overall survival in patients with kidney renal clear cell carcinoma via an integrated bioinformatics analysis

“…SLC16A12 is a member of the SLC16A family, and its function is not known. A recent study showed that SLC16A12 can be a prognostic factor for patients in KIRC, indicating that SLC16A12 might be a critical tumor suppressor (Mei et al 2019 ). ZIC2 is a member of the ZIC family and is a transcription factor (Inaguma et al 2015 ).…”

A pan-cancer analysis revealed the role of the SLC16 family in cancer

“…Moreover, studies have shown that SLC16A7 is associated with the stem cell characteristics of tumors [ 49 ]. Mei et al found that the expression of SLC16A12 was decreased in renal clear cell carcinoma and was associated with poor prognosis, which has a good prognostic guiding significance [ 50 ]. However, studies on SLC16A4, SLC16A10, SLC16A11, SLC16A13, and SLC16A14 in cancer are still lacking.…”

Decreased SLC39A1 (Solute carrier family 39 member 1) expression predicts unfavorable prognosis in patients with early-stage hepatocellular carcinoma

“…The staining intensity was scored from 0 to 3, namely, 0: negative, 1: low, 2: moderate, and 3: high. Semi-quantitative analysis of the IHC staining was performed based on the percentage of positively stained cells and staining density by two pathologists and this analysis method has been previously applied [ 11 ]. Immunostained sections were snapshot using a microscope (Olympus Corporation).…”